对青光眼和眼睛健康闪亮的光
Millions are blind because of glaucoma but connecting with patients sooner could help them get to a doctor before they lose their vision.\r\n"}}" id="text-a20aa1927f" class="cmp-text">
计是盲人因青光眼而联系病人早可以帮助他们得到一个医生之前失去视力。
提高意识视觉相关的疾病
For many people across the globe, vision is something they may take for granted - that is, until they or someone they know is affected by prevalent and potentially devastating eye diseases. \n
It's estimated more than 4 million people around the world are blind as a result of primary glaucoma. That's more than 12 percent of all global blindness.1
\nAbbVie aims to educate people in the U.S. on the seriousness and prevalence of the disease through the MyGlaucoma campaign.
\n"}}" id="text-0d4da97ad6" class="cmp-text">全球对许多人来说,视觉是他们可能会认为理所当然,直到他们或者他们认识的人是受到普遍的和潜在的毁灭性的眼疾。
据估计全球有400万多人盲目结果原发性青光眼。超过12%的全球失明。1
AbbVie旨在教育人们在美国和流行疾病的严重性MyGlaucoma运动。
帮助最脆弱的
There’s even more work being done to reach people around the world.
\nAbbVie also partners with Sightsavers, and the International Agency for the Prevention of Blindness, a non-profit whose goal is to prevent avoidable blindness and save the sight of some of the world’s most vulnerable people.\n"}}" id="text-fc337b61ee" class="cmp-text">
\nAbbVie also partners with Sightsavers, and the International Agency for the Prevention of Blindness, a non-profit whose goal is to prevent avoidable blindness and save the sight of some of the world’s most vulnerable people.\n"}}" id="text-fc337b61ee" class="cmp-text">
甚至还有更多的工作做到达世界各地的人们。
AbbVie也合作伙伴Sightsavers,国际机构的预防失明,一个非盈利的目标是预防可避免的盲症和保存的一些世界上最脆弱的人。
在尼日利亚,AbbVie提供资助协调50护眼专业人员的培训。
在尼日利亚,保持视线帮助发展当地驱动青光眼为卫生保健专业人员的培训协议。
程序调用时,保持视力,在印度帮助提供培训卫生保健专业人士。
AbbVie与两个预见组织合作,帮助解决缺医少药人群从青光眼可避免盲症。
The program is called Keep Sight where AbbVie helps to provide training for eyecare professionals in Nigeria and India to screen high risk populations, ensure early and accurate diagnosis and provide appropriate care to make a positive impact on people at risk or living with glaucoma.\r\n
In just one year, ophthalmologists conducted more than more than 12,000 eye screenings and referred more than 1,000 glaucoma-related cases.
\r\n"}}" id="text-df41aee6c2" class="cmp-text">程序被称为保持视线AbbVie有助于提供培训的眼科专家在尼日利亚和印度筛选高危人群,确保早期准确诊断和提供适当的护理对人产生积极的影响与青光眼或生活风险。
在仅仅一年,眼科医生进行了超过12000多名眼科筛查和glaucoma-related案件超过1000起。
看到了科学
On top of making more people aware of the difficulties that glaucoma can cause, AbbVie is dedicated to researching and developing innovative solutions to preserve people’s vision. Leading the charge since 2005 is Mike Robinson, MD, vice president, clinical development, ophthalmology. Prior to joining the company, Robinson was a clinical staff fellow at the National Institutes of Health, but it’s the emotional moments of patient care that drive him to continue looking for new ways to restore people’s vision.\r\n
“There is such great satisfaction after removing a blinding cataract in a patient and seeing them cry tears of joy the next day when they realize their vision has returned,” says Robinson.
\r\n"}}" id="text-d87ce98391" class="cmp-text">上让更多的人了解青光眼可导致的困难,AbbVie致力于研究和开发创新的解决方案来保护人们的视野。引领自2005年以来是迈克·罗宾逊,医学博士,副总裁,临床发展,眼科。狗万正网地址在加入公司之前,鲁滨逊是一个临床人员美国国立卫生研究院的研究员,但病人护理的情感的时刻,让他继续寻找新的方法来恢复人的愿景。
“有这样伟大的满意后移除一个眩目的白内障患者,看到他们快乐的泪水哭第二天当他们意识到他们的视力已经恢复,”罗宾逊说。
He combines his years of caring for patients with his passion for science. Robinson believes ophthalmology is the perfect fit. “I was drawn to eye health and vision restoration because of the rich history of innovation this area of medicine holds,” says Robinson. “Ophthalmology is even in the forefront of stem cell research and regenerative medicine, which is exciting for the future of eye care.”\r\n"}}" id="text-5df8fc6200" class="cmp-text">
他结合他多年的照顾病人,他对科学的热情。罗宾逊认为,眼科学是完美的健康。“我是眼睛健康和视力恢复,因为创新医学这一领域拥有的丰富的历史,”罗宾逊说。“眼科是即使在干细胞研究和再生医学的前沿,这是令人兴奋的眼保健的未来。”
眼睛专注于创新
While eye care may seem simple, with many vision issues being solved by people wearing glasses contact lenses, or even using eye drops, the reality is what works for some does not work for others. One of the areas Robinson has been focused on in his research has been addressing the challenge of glaucoma patients not managing their eye health correctly and losing their vision.\r\n"}}" id="text-ddca84ad5d" class="cmp-text">
虽然眼保健看起来简单,许多人戴眼镜视力问题被解决隐形眼镜,甚至使用眼药水,现实是不适合什么工作。罗宾逊的地区之一,在他的研究都集中在应对挑战的青光眼患者不正确地管理自己的眼睛健康,失去视力。
“We continue to look for solutions in our clinical trials. Our goal has been and continues to be identifying ways to meet people where they are in their ability to preserve their vision, and our clinical trials are looking at ways to provide glaucoma patients additional options,” says Robinson.\r\n
Robinson and his team’s work isn’t over. They continue to collaborate with key opinion leaders in the field of glaucoma care while also connecting with people living with glaucoma and their caregivers so they have access to resources so they can better understand their eye health.
\r\n“We will always incorporate patient needs into our science and partnering with well-known voices in eye care to frontline ophthalmologists will allow us to help more people continue to see clearly.”
\r\n"}}" id="text-5fd8cc15a4" class="cmp-text">“我们继续寻找解决方案的临床试验。我们的目标一直并将继续是识别方法来满足不同人的能力保护他们的视力,和我们的临床试验正在设法提供青光眼患者额外的选择,”罗宾逊说。
鲁滨逊和他的团队的工作还没有结束。他们继续合作与关键领域的意见领袖青光眼护理,同时结合青光眼患者和他们的照顾者,所以他们对资源的访问,这样他们就可以更好地理解他们的眼睛健康。
“我们总是把病人需要融入科学和与著名的声音在眼部护理前线眼科医生将使我们能够帮助更多的人继续看manbet体育网址得清楚。”
引用:
1. Blindness and vision impairment. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
\nWorld Health Organization.
\nDate Accessed December 5, 2022. Date Published October 13, 2022.\n"}}" id="text-c99efc426e" class="cmp-text">
\nWorld Health Organization.
\nDate Accessed December 5, 2022. Date Published October 13, 2022.\n"}}" id="text-c99efc426e" class="cmp-text">
1。 失明和视力障碍https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
世界卫生组织。
访问日期12月5日,2022年。出版日期2022年10月13日。
Media inquiries:
\r\nabbviemediarelations@abbvie.com
\r\n
\r\n\r\n"}}" id="text-d9a51fd01b" class="cmp-text">
\r\nabbviemediarelations@abbvie.com
\r\n
\r\n\r\n"}}" id="text-d9a51fd01b" class="cmp-text">
媒体询问:
(电子邮件保护)
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-ed79875d09" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
